Hikaru Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hikaru Sasaki has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
Kazunari Yoshida
Department of Neurosurgery, Keio University School of Medicine, Shinjuku-ku, Japan
19 shared publicationsKentaro Ohara
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
10 shared publicationsYohei Kitamura
Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan
9 shared publicationsMasahiro Toda
Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan
7 shared publications- Ryota Tamura
Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan
7 shared publications Yuichi Hirose
Department of Neurosurgery, Fujita Health University School of Medicine, Toyoake, Japan
5 shared publications
Latest Publications
- Open Access
Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching
Background/Objectives: The role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis. Methods: We retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21–30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared. Results: All patients had GB (31 IDH-wild-type, 2 IDH-mutant). Median KPS improved after neoBev (71 to 83), while no improvement was observed in controls. After matching, median PFS and OS did not differ between the neoBev and control groups (7.4 vs. 8.6 months and 13.4 vs. 13.8 months, respectively). Exploratory analyses in the neoBev cohort showed that greater T1Gd volume reduction was associated with improved PFS and OS, whereas FLAIR changes were not. Conclusions: Preoperative neoBev did not improve survival compared with standard chemoradiotherapy. However, it was associated with improved functional status, and exploratory imaging findings suggested associations between early radiographic response and outcome. NeoBev should not be used routinely but may have a contextual role in selected patients with perioperative challenges.
Open AccessValidation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching
Background/Objectives: The role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis. Methods: We retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21–30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared. Results: All patients had GB (31 IDH-wild-type, 2 IDH-mutant). Median KPS improved after neoBev (71 to 83), while no improvement was observed in controls. After matching, median PFS and OS did not differ between the neoBev and control groups (7.4 vs. 8.6 months and 13.4 vs. 13.8 months, respectively). Exploratory analyses in the neoBev cohort showed that greater T1Gd volume reduction was associated with improved PFS and OS, whereas FLAIR changes were not. Conclusions: Preoperative neoBev did not improve survival compared with standard chemoradiotherapy. However, it was associated with improved functional status, and exploratory imaging findings suggested associations between early radiographic response and outcome. NeoBev should not be used routinely but may have a contextual role in selected patients with perioperative challenges.
- Open Access
- 19 December 2025
- Published by MDPI AG in Preprints.org
Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching
Background/Objectives: This study assessed the clinical effects of preoperative neoadjuvant bevacizumab (neoBev) on newly diagnosed glioblastoma (GB) and investigated imaging-based predictors of outcome. Methods: We retrospectively reviewed 33 patients who received neoBev (10 mg/kg) between 2015 and 2024. Surgery was performed 21–30 days after treatment. Controls comprised 33 patients treated with standard chemoradiotherapy (radiation plus temozolomide) selected through propensity score matching. We assessed changes in performance status, extent of resection (EOR), and volumetric alterations on gadolinium-enhanced T1-weighted imaging (T1Gd) and fluid-attenuated inversion recovery (FLAIR). Median progression-free survival (mPFS) and median overall survival (mOS) were compared. Imaging responders were defined using receiver operating characteristic-derived thresholds. Results: All patients had GB (31 with isocitrate dehydrogenase (IDH)1 wild-type, 2 with IDH-mutant). Median Karnofsky Performance Status improved significantly after treatment in the NeoBev group (from 71 to 83), but remained unchanged in Controls. After matching, mPFS and mOS were 10.2 and 17.9 months with neoBev, and 13.3 and 18.2 months in Controls, respectively. Within the neoBev cohort, T1Gd responders (>37% reduction) achieved longer mPFS and mOS than non-responders. EOR-stratified analysis showed that outcomes favored standard therapy in cases with gross total resection, while subtotal resection cases demonstrated comparable or slightly better OS with neoBev. Conclusions: Preoperative neoBev improved functional status and identified an imaging-defined subgroup with favorable prognosis, although survival was not superior to that with standard therapy. NeoBev may benefit selected patients with limited resectability of newly diagnosed GB.
- 19 December 2025
- Published by MDPI AG in Preprints.org
Open AccessValidation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching
Background/Objectives: This study assessed the clinical effects of preoperative neoadjuvant bevacizumab (neoBev) on newly diagnosed glioblastoma (GB) and investigated imaging-based predictors of outcome. Methods: We retrospectively reviewed 33 patients who received neoBev (10 mg/kg) between 2015 and 2024. Surgery was performed 21–30 days after treatment. Controls comprised 33 patients treated with standard chemoradiotherapy (radiation plus temozolomide) selected through propensity score matching. We assessed changes in performance status, extent of resection (EOR), and volumetric alterations on gadolinium-enhanced T1-weighted imaging (T1Gd) and fluid-attenuated inversion recovery (FLAIR). Median progression-free survival (mPFS) and median overall survival (mOS) were compared. Imaging responders were defined using receiver operating characteristic-derived thresholds. Results: All patients had GB (31 with isocitrate dehydrogenase (IDH)1 wild-type, 2 with IDH-mutant). Median Karnofsky Performance Status improved significantly after treatment in the NeoBev group (from 71 to 83), but remained unchanged in Controls. After matching, mPFS and mOS were 10.2 and 17.9 months with neoBev, and 13.3 and 18.2 months in Controls, respectively. Within the neoBev cohort, T1Gd responders (>37% reduction) achieved longer mPFS and mOS than non-responders. EOR-stratified analysis showed that outcomes favored standard therapy in cases with gross total resection, while subtotal resection cases demonstrated comparable or slightly better OS with neoBev. Conclusions: Preoperative neoBev improved functional status and identified an imaging-defined subgroup with favorable prognosis, although survival was not superior to that with standard therapy. NeoBev may benefit selected patients with limited resectability of newly diagnosed GB.
- Open Access
- 13 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Development of microsurgical forceps equipped with haptic technology for in situ differentiation of brain tumors during microsurgery
The stiffness of human cancers may be correlated with their pathology, and can be used as a biomarker for diagnosis, malignancy prediction, molecular expression, and postoperative complications. Neurosurgeons perform tumor resection based on tactile sensations. However, it takes years of surgical experience to appropriately distinguish brain tumors from surrounding parenchymal tissue. Haptics is a technology related to the touch sensation. Haptic technology can amplify, transmit, record, and reproduce real sensations, and the physical properties (e.g., stiffness) of an object can be quantified. In the present study, glioblastoma (SF126-firefly luciferase-mCherry [FmC], U87-FmC, U251-FmC) and malignant meningioma (IOMM-Lee-FmC, HKBMM-FmC) cell lines were transplanted into nude mice, and the stiffness of tumors and normal brain tissues were measured using our newly developed surgical forceps equipped with haptic technology. We found that all five brain tumor tissues were stiffer than normal brain tissue (p < 0.001), and that brain tumor pathology (three types of glioblastomas, two types of malignant meningioma) was significantly stiffer than normal brain tissue (p < 0.001 for all). Our findings suggest that tissue stiffness may be a useful marker to distinguish brain tumors from surrounding parenchymal tissue during microsurgery, and that haptic forceps may help neurosurgeons to sense minute changes in tissue stiffness.
- 13 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessDevelopment of microsurgical forceps equipped with haptic technology for in situ differentiation of brain tumors during microsurgery
The stiffness of human cancers may be correlated with their pathology, and can be used as a biomarker for diagnosis, malignancy prediction, molecular expression, and postoperative complications. Neurosurgeons perform tumor resection based on tactile sensations. However, it takes years of surgical experience to appropriately distinguish brain tumors from surrounding parenchymal tissue. Haptics is a technology related to the touch sensation. Haptic technology can amplify, transmit, record, and reproduce real sensations, and the physical properties (e.g., stiffness) of an object can be quantified. In the present study, glioblastoma (SF126-firefly luciferase-mCherry [FmC], U87-FmC, U251-FmC) and malignant meningioma (IOMM-Lee-FmC, HKBMM-FmC) cell lines were transplanted into nude mice, and the stiffness of tumors and normal brain tissues were measured using our newly developed surgical forceps equipped with haptic technology. We found that all five brain tumor tissues were stiffer than normal brain tissue (p < 0.001), and that brain tumor pathology (three types of glioblastomas, two types of malignant meningioma) was significantly stiffer than normal brain tissue (p < 0.001 for all). Our findings suggest that tissue stiffness may be a useful marker to distinguish brain tumors from surrounding parenchymal tissue during microsurgery, and that haptic forceps may help neurosurgeons to sense minute changes in tissue stiffness.
- 2 April 2024
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 41 (2) , 43-49
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted is known for their relative chemosensitivity and indolent clinical course among diffuse gliomas of adult type. Based on the data from phase 3 clinical trials, the standard of post-surgical care for those tumors is considered to be initial chemoradiotherapy regardless of histopathological grade, particularly with PCV. However, partly due to its renewed definition in late years, prognostic factors in patients with those tumors are not well established. Moreover, the survival rate declines over 15 years, with only a 37% OS rate at 20 years for grade 3 tumors, even with the current standard of care. Given that most of this disease occurs in young or middle-aged adults, further improvements in treatment and management are necessary. Here, we discuss prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy in those tumors.
- 2 April 2024
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 41 (2) , 43-49
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted is known for their relative chemosensitivity and indolent clinical course among diffuse gliomas of adult type. Based on the data from phase 3 clinical trials, the standard of post-surgical care for those tumors is considered to be initial chemoradiotherapy regardless of histopathological grade, particularly with PCV. However, partly due to its renewed definition in late years, prognostic factors in patients with those tumors are not well established. Moreover, the survival rate declines over 15 years, with only a 37% OS rate at 20 years for grade 3 tumors, even with the current standard of care. Given that most of this disease occurs in young or middle-aged adults, further improvements in treatment and management are necessary. Here, we discuss prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy in those tumors.
- Open Access
- 31 January 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 166 (3) , 557-567
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Purpose: This multi-institutional phase I/II study was conducted to confirm the safety and explore the clinical utility of preoperative Bevacizumab (Bev) for newly diagnosed glioblastoma (GB). Methods: Patients were enrolled based on magnetic resonance imaging (MRI) findings typically suggestive of GB. Preoperative Bev and temozolomide (TMZ) were administered at doses of 10 mg/kg on day 0 and 150 mg/m2 on days 1–5, respectively. Surgical resection was performed between days 21 and 30, inclusive. The safety and efficacy were evaluated in a total of 15 cases by progression-free survival (PFS), changes in tumor volume, Karnofsky Performance Scale (KPS) and Mini-Mental State Examination (MMSE) scores after preoperative therapy. Results: Tumor resection was performed on a mean of day 23.7. Pathological diagnosis was GB, isocitrate dehydrogenase (IDH)-wildtype in 14 cases and GB, IDH-mutant in 1 case. Severe adverse events possibly related to preoperative Bev and TMZ were observed in 2 of the 15 patients, as wound infection and postoperative hematoma and thrombocytopenia. KPS and MMSE scores were significantly improved with preoperative therapy. Tumor volume was decreased in all but one case on T1-weighted imaging with contrast-enhancement (T1CE) and in all cases on fluid-attenuated inversion recovery, with mean volume decrease rates of 36.2% and 54.0%, respectively. Median PFS and overall survival were 9.5 months and 16.5 months, respectively. Conclusion: Preoperative Bev and TMZ is safe as long as the instructions are followed. The strategy might be useful for GB in some patients, not only reducing tumor burden, but also improving patient KPS preoperatively. Trial Registration Number: UMIN000025579, jRCT1031180233 https://jrct.niph.go.jp/latest-detail/jRCT1031180233. Registration Date: Jan. 16, 2017
- 31 January 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 166 (3) , 557-567
Open AccessAn exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
Purpose: This multi-institutional phase I/II study was conducted to confirm the safety and explore the clinical utility of preoperative Bevacizumab (Bev) for newly diagnosed glioblastoma (GB). Methods: Patients were enrolled based on magnetic resonance imaging (MRI) findings typically suggestive of GB. Preoperative Bev and temozolomide (TMZ) were administered at doses of 10 mg/kg on day 0 and 150 mg/m2 on days 1–5, respectively. Surgical resection was performed between days 21 and 30, inclusive. The safety and efficacy were evaluated in a total of 15 cases by progression-free survival (PFS), changes in tumor volume, Karnofsky Performance Scale (KPS) and Mini-Mental State Examination (MMSE) scores after preoperative therapy. Results: Tumor resection was performed on a mean of day 23.7. Pathological diagnosis was GB, isocitrate dehydrogenase (IDH)-wildtype in 14 cases and GB, IDH-mutant in 1 case. Severe adverse events possibly related to preoperative Bev and TMZ were observed in 2 of the 15 patients, as wound infection and postoperative hematoma and thrombocytopenia. KPS and MMSE scores were significantly improved with preoperative therapy. Tumor volume was decreased in all but one case on T1-weighted imaging with contrast-enhancement (T1CE) and in all cases on fluid-attenuated inversion recovery, with mean volume decrease rates of 36.2% and 54.0%, respectively. Median PFS and overall survival were 9.5 months and 16.5 months, respectively. Conclusion: Preoperative Bev and TMZ is safe as long as the instructions are followed. The strategy might be useful for GB in some patients, not only reducing tumor burden, but also improving patient KPS preoperatively. Trial Registration Number: UMIN000025579, jRCT1031180233 https://jrct.niph.go.jp/latest-detail/jRCT1031180233. Registration Date: Jan. 16, 2017
- Open Access
- 15 July 2023
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 44 (2) , 85-94
Photodynamic Therapy for Primary Malignant Brain Tumors: Initial Experience at Keio University Hospital
光線力学的療法(photodynamic therapy: PDT)を実施した悪性脳腫瘍患者19例の治療経過を追跡した.このうち神経膠腫は17例で,WHO2016におけるGrade IVが13例(初発8例,再発5例),Grade IIIが4例(初発1例,再発3例)であった.9例ではカルムスチンウエハーの留置を併用した.良好な局所制御を示した例が見られた一方,9例(Grade IVの6例,Grade IIIの3例)でPDT後の再発を認めた.因果関係は不明だが,術後に頭蓋内出血で死亡した1例があった.初発膠芽腫の無増悪生存期間中央値は15か月,6か月の無増悪生存率は51%であった.手術映像の検討によると,PDTが十分に行われた領域での局所制御は向上する可能性があるが,レーザーが到達しない部位での再発や播種の予防は困難と思われた.可及的広範囲へのレーザー照射ならびに慎重な経過観察が治療成績の向上に必要である.
- 15 July 2023
- Published by Japan Society for Laser Surgery and Medicine in THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE
- Vol. 44 (2) , 85-94
Open AccessPhotodynamic Therapy for Primary Malignant Brain Tumors: Initial Experience at Keio University Hospital
光線力学的療法(photodynamic therapy: PDT)を実施した悪性脳腫瘍患者19例の治療経過を追跡した.このうち神経膠腫は17例で,WHO2016におけるGrade IVが13例(初発8例,再発5例),Grade IIIが4例(初発1例,再発3例)であった.9例ではカルムスチンウエハーの留置を併用した.良好な局所制御を示した例が見られた一方,9例(Grade IVの6例,Grade IIIの3例)でPDT後の再発を認めた.因果関係は不明だが,術後に頭蓋内出血で死亡した1例があった.初発膠芽腫の無増悪生存期間中央値は15か月,6か月の無増悪生存率は51%であった.手術映像の検討によると,PDTが十分に行われた領域での局所制御は向上する可能性があるが,レーザーが到達しない部位での再発や播種の予防は困難と思われた.可及的広範囲へのレーザー照射ならびに慎重な経過観察が治療成績の向上に必要である.
- 9 March 2023
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 40 (2) , 109-123
Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence
Pilocytic astrocytomas (PAs) are benign tumors. However, clinically aggressive PAs despite benign histology have been reported, and histological and molecular risk factors for prognosis have not been elucidated. 38 PAs were studied for clinical, histological, and molecular factors, including tumor location, extent of resection, post-operative treatment, glioma-associated molecules (IDH1/2, ATRX, BRAF, FGFR1, PIK3CA, H3F3A, p53, VEGF, Nestin, PD-1/PD-L1), CDKN2A/B deletion, and chromosomal number aberrations, to see if there is any correlation with patient’s progression-free survival (PFS). Brainstem/spinal location, extent of resection and post-operative treatment, and VEGF-A, Nestin and PD-L1 expression, copy number gain of chromosome 7q or 19, TP53 mutation were significantly associated with shorter PFS. None of the histological parameters was associated with PFS. Multivariate analyses demonstrated that high Nestin expression, gain of 7q or 19, and extent of removal were independently predictive for early tumor recurrence. The brainstem/spinal PAs appeared distinct from those in the other sites in terms of molecular characteristics. Clinically aggressive PAs despite benign histology exhibited high Nestin expression. Brainstem/spinal location, extent of resection and some molecular factors including Nestin expression and gains of 7q and 19, rather than histological parameters, may be associated with early tumor recurrence in PAs.
- 9 March 2023
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 40 (2) , 109-123
Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence
Pilocytic astrocytomas (PAs) are benign tumors. However, clinically aggressive PAs despite benign histology have been reported, and histological and molecular risk factors for prognosis have not been elucidated. 38 PAs were studied for clinical, histological, and molecular factors, including tumor location, extent of resection, post-operative treatment, glioma-associated molecules (IDH1/2, ATRX, BRAF, FGFR1, PIK3CA, H3F3A, p53, VEGF, Nestin, PD-1/PD-L1), CDKN2A/B deletion, and chromosomal number aberrations, to see if there is any correlation with patient’s progression-free survival (PFS). Brainstem/spinal location, extent of resection and post-operative treatment, and VEGF-A, Nestin and PD-L1 expression, copy number gain of chromosome 7q or 19, TP53 mutation were significantly associated with shorter PFS. None of the histological parameters was associated with PFS. Multivariate analyses demonstrated that high Nestin expression, gain of 7q or 19, and extent of removal were independently predictive for early tumor recurrence. The brainstem/spinal PAs appeared distinct from those in the other sites in terms of molecular characteristics. Clinically aggressive PAs despite benign histology exhibited high Nestin expression. Brainstem/spinal location, extent of resection and some molecular factors including Nestin expression and gains of 7q and 19, rather than histological parameters, may be associated with early tumor recurrence in PAs.
- 15 March 2022
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 39 (2) , 79-87
The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas
The relevance of oligodendroglial histological features to patient prognoses is controversial. 93 LrGGs resected for about 2 decades were re-assessed based on WHO2007 with special interest to pure oligodendroglial diagnosis (oligodendroglioma or anaplastic oligodendroglioma) and presence of CFO features. Those histological features, patients OS, and tumor chromosomal/genetic characteristics were correlated each other in each of the 3 IDH-1p/19q-based molecular groups. There was significant association between 1p19q status with the oligodendroglial histological diagnosis as well as presence of CFO in the entire cohort. The oligodendroglial diagnosis was associated with longer OS in IDHmut/codel group; however, this association was not significant in the multivariate analyses. In IDHmut/noncodel and IDH-wildtype groups, the oligodendroglial diagnosis was not associated with patient OS. Presence of CFO was not associated with patient OS in any molecular groups. Gain of 8q was associated with the oligodendroglial diagnosis in IDHmut/noncodel group. Neither the oligodendroglial diagnosis nor CFO was predictive for the methylation status of the MGMT gene in any molecular groups. The oligodendroglial histological features are not independently predictive of either patient prognosis or chemotherapeutic response in LrGGs, leaving the possibility of marginal favorable association only in IDHmut/codel tumors.
- 15 March 2022
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 39 (2) , 79-87
The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas
The relevance of oligodendroglial histological features to patient prognoses is controversial. 93 LrGGs resected for about 2 decades were re-assessed based on WHO2007 with special interest to pure oligodendroglial diagnosis (oligodendroglioma or anaplastic oligodendroglioma) and presence of CFO features. Those histological features, patients OS, and tumor chromosomal/genetic characteristics were correlated each other in each of the 3 IDH-1p/19q-based molecular groups. There was significant association between 1p19q status with the oligodendroglial histological diagnosis as well as presence of CFO in the entire cohort. The oligodendroglial diagnosis was associated with longer OS in IDHmut/codel group; however, this association was not significant in the multivariate analyses. In IDHmut/noncodel and IDH-wildtype groups, the oligodendroglial diagnosis was not associated with patient OS. Presence of CFO was not associated with patient OS in any molecular groups. Gain of 8q was associated with the oligodendroglial diagnosis in IDHmut/noncodel group. Neither the oligodendroglial diagnosis nor CFO was predictive for the methylation status of the MGMT gene in any molecular groups. The oligodendroglial histological features are not independently predictive of either patient prognosis or chemotherapeutic response in LrGGs, leaving the possibility of marginal favorable association only in IDHmut/codel tumors.
- 31 October 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 155 (3) , 235-246
Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy
Purpose Lower grade gliomas with 1p/19q codeletion are often responsive to chemotherapy, and several of these have been treated using upfront chemotherapy and subsequent resection following tumor volume decrease. This study aimed to elucidate the histological changes and the mechanism of recurrence after alkylating agent chemotherapy in 1p/19-codeleted gliomas. Methods Fourteen 1p/19q-codeleted gliomas resected following tumor volume decrease after alkylating agent chemotherapy were included and compared with their pre-chemotherapy specimens. Histological changes were investigated using hematoxylin–eosin staining, and changes in proliferative activity, status of glioma stem cells (GSCs), and tumor-infiltrating macrophages were assessed using immunohistochemistry for Ki-67/MIB-1, CD68 as a pan-macrophage/monocyte marker, CD163 as a presumed marker of M2 polarity, and nestin and CD133 as markers of GSCs. Results The most frequent histological findings following chemotherapy included a sparse glial background and abundant foamy cell infiltration. The Ki-67/MIB-1 index decreased and the number of CD68 + cells increased after chemotherapy. The increasing rate of CD68 + cells in the post-/pre-chemotherapy specimens was inversely correlated with patient prognosis but not tumor response. The number of CD163 + cells, M2/M1 + M2 ratio, and the ratio of GSCs to total tumor cells increased after chemotherapy, and those in the post-chemotherapy specimens were negatively correlated with patient prognosis. There was a correlation between the M2/M1 + M2 ratio and the ratio of GSCs in both pre- and post-chemotherapy specimens. Conclusion GSCs in conjunction with M2 macrophages constitute the mechanism of resistance to and recurrence after alkylating agent chemotherapy in 1p/19q-codeleted gliomas.
- 31 October 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 155 (3) , 235-246
Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy
Purpose Lower grade gliomas with 1p/19q codeletion are often responsive to chemotherapy, and several of these have been treated using upfront chemotherapy and subsequent resection following tumor volume decrease. This study aimed to elucidate the histological changes and the mechanism of recurrence after alkylating agent chemotherapy in 1p/19-codeleted gliomas. Methods Fourteen 1p/19q-codeleted gliomas resected following tumor volume decrease after alkylating agent chemotherapy were included and compared with their pre-chemotherapy specimens. Histological changes were investigated using hematoxylin–eosin staining, and changes in proliferative activity, status of glioma stem cells (GSCs), and tumor-infiltrating macrophages were assessed using immunohistochemistry for Ki-67/MIB-1, CD68 as a pan-macrophage/monocyte marker, CD163 as a presumed marker of M2 polarity, and nestin and CD133 as markers of GSCs. Results The most frequent histological findings following chemotherapy included a sparse glial background and abundant foamy cell infiltration. The Ki-67/MIB-1 index decreased and the number of CD68 + cells increased after chemotherapy. The increasing rate of CD68 + cells in the post-/pre-chemotherapy specimens was inversely correlated with patient prognosis but not tumor response. The number of CD163 + cells, M2/M1 + M2 ratio, and the ratio of GSCs to total tumor cells increased after chemotherapy, and those in the post-chemotherapy specimens were negatively correlated with patient prognosis. There was a correlation between the M2/M1 + M2 ratio and the ratio of GSCs in both pre- and post-chemotherapy specimens. Conclusion GSCs in conjunction with M2 macrophages constitute the mechanism of resistance to and recurrence after alkylating agent chemotherapy in 1p/19q-codeleted gliomas.